Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:INCR

InterCure Q4 2025 Earnings Report

InterCure logo
$1.10 +0.06 (+5.94%)
Closing price 06/30/2026 03:59 PM Eastern
Extended Trading
$1.07 -0.03 (-3.09%)
As of 06/30/2026 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

InterCure EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

InterCure Revenue Results

Actual Revenue
$23.15 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

InterCure Announcement Details

Quarter
Q4 2025
Date
4/30/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

InterCure Earnings Headlines

InterCure Secures NIS 22 Million Private Placement With Potential to Rise to NIS 54 Million for Global Expansion
June 22, 2026  |  quiverquant.comQ
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315301/0/en/InterCure-Secures-NIS-22-Million-in-Private-Placement-Financing-Led-by-Leading-Pharma-Focused-Hedge-Funds.html
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
 |  Paradigm Press (Ad)
InterCure Ltd. Completes First Tranche of Botanico Acquisition to Enhance International Medical Cannabis Platform
June 15, 2026  |  quiverquant.comQ
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
June 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/15/3311859/0/en/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition.html
InterCure Ltd. Reports NIS 270 Million Revenue and Positive Cash Flow for 2025 Amid Recovery Efforts
April 30, 2026  |  quiverquant.comQ
See More InterCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InterCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InterCure and other key companies, straight to your email.

About InterCure

InterCure (NASDAQ:INCR) Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives. The company’s in-house R&D team works in collaboration with academic and medical institutions to explore novel therapeutic applications of cannabinoids. InterCure’s product portfolio includes standardized oils, capsules and topical formulations designed to address specific clinical indications and patient preferences.

Beyond its domestic footprint, InterCure has entered strategic partnerships aimed at exporting medical cannabis products to select European and Latin American markets. These collaborations are structured to meet local regulatory requirements and quality standards, offering a pathway for InterCure’s intellectual property and high-potency strains to reach new patient populations.

Looking forward, InterCure is focused on scaling its production capacity, enhancing process efficiencies and expanding its international presence through licensing agreements and joint ventures. The company continues to invest in clinical research, advanced processing technologies and new product development as it seeks to establish a broader footprint in the evolving global medical cannabis industry.

View InterCure Profile
Earnings Tools